Please enable Javascript to use all features and improve your user experience.
EHC 2022
Programme
Posters
People
Search
EN
All people
Robert Croop
Sort by Type
Date
Speaker
09 Dec
15:40
–
15:45
3 Min.
2 Min.
ePoster
P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
CGRP inhibitors in the clinic, Migraine
09 Dec
16:40
–
16:45
3 Min.
2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09 Dec
16:50
–
16:55
3 Min.
2 Min.
ePoster
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
CGRP inhibitors in the clinic, Migraine
Further involvements
09 Dec
15:30
–
15:35
3 Min.
2 Min.
ePoster
P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
CGRP inhibitors in the clinic, Migraine
09 Dec
15:40
–
15:45
3 Min.
2 Min.
ePoster
P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
CGRP inhibitors in the clinic, Migraine
09 Dec
15:40
–
15:45
3 Min.
2 Min.
ePoster
P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
CGRP inhibitors in the clinic, Migraine
09 Dec
15:45
–
15:50
3 Min.
2 Min.
ePoster
P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
CGRP inhibitors in the clinic, Migraine
09 Dec
16:40
–
16:45
3 Min.
2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09 Dec
16:45
–
16:50
3 Min.
2 Min.
ePoster
P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09 Dec
16:50
–
16:55
3 Min.
2 Min.
ePoster
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
CGRP inhibitors in the clinic, Migraine
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy